Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Save to My Library
Look up keyword
Like this
2Activity
0 of .
Results for:
No results containing your search query
P. 1
Novartis (Bangladesh) an Overview

Novartis (Bangladesh) an Overview

Ratings: (0)|Views: 999|Likes:
Published by Rasidul Hasan Sumon

More info:

Published by: Rasidul Hasan Sumon on Oct 14, 2010
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as TXT, PDF, TXT or read online from Scribd
See more
See less

04/03/2013

pdf

text

original

 
1Novartis (Bangladesh) Limited: an overview2.1 Formation path of NovartisThe name Novartis is derived from the Latin "Novae Artes" which means new skills.On March 07, 1996, an earthshaking announcement was made to the business world:Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, had agreed to become one. Novartis, as the new company was called, was at that time the result of the largest corporate merger in history. Both Sandoz and Ciba-Geigyalready had a rich history of their own. 2.2 MissionWe want to discover, develop and successfully market innovative products to curediseases, to ease suffering, and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company.2.3 AspirationsWe want to be recognized for having a positive impact on people's lives with ourproducts, meeting needs and even surpassing external expectations. We strive to create sustainable earnings growth, ranking in the top quartile ofthe industry and securing long-term business success. We want to build a reputation for an exciting workplace in which people can realize their professional ambitions.We strive for a motivating environment where creativity and effectiveness are encouraged and where cutting-edge technologies are applied. In addition, we want to contribute to society through our economic contribution, through the positiveenvironmental and social benefits of our products, and through open dialogue with our stakeholders.2.3 Novartis (Bangladesh) Limited: Company HistoryThe state-of-art manufacturer plant of Novartis (Bangladesh) Limited was established in 1989 with an annual capacity of producing 200 million tablets/capsules.In 2002 production facilities expand and with this expansion of the plant capacity increased to annual production of 500 million tablets/capsules.From early 1970, Novartis- then well known Ciba-Geigy- engaged in trading with various chemical and healthcare products in Bangladesh. The Bangladesh group company was introduced in 1973 with the 40% participation of Bangladesh Chemical Industries Corporation (BCIC). In a first venture agreement of both partners in 1980 the investment in a crop protection formulation plant in Chittagong was implemented.In a second joint venture agreement in 1988 NBL and BCIC invested in a pharmaceuticals production plant in Tongi, which operated as from 1990 with life-saving products fitting the needs of the country.In 2000, Novartis decided to go on a global basis to spin-off the agro businessand henceforth to concentrate on healthcare. This affected also the Bangladesh g
 
roup company.The former crop protection business of NBL at present continuing with the business partner BCIC, under the authority of Syngenta as a separate legal entity.The Sandoz Business Unit of NBL is the owner of this plant. The plant is locatedabout 20 kilometers north of Dhaka city and covers an area of about 36634 sq meters. The site is surrounded in the north 10 m wide road beyond the village of Tongi, in the west bordering on fields, in the east to a pharmaceutical factory of Eskayef, and in the south and southwest the side is adjacent to the river Turag.The site comprises of building of pharmaceutical production, Quality Control andIT, for warehouse, for engineering support, for product development, for animalhealth production for office and canteen, for storage of inflammable substances, for diesel storage of generator, for catering, for incinerator, for pump house, for gate, for waste water treatment plant, for car workshop, for guest house and guard barrack.The first buildings were raised in 1989 and commercial manufacturing was initiated in 1990.Pharmaceutical Production comprises of two sections dealing with Manufacturing and Packaging. Most of the active substances used in the manufacturing are supplied by Novartis International Limited, Basel & Sandoz GmbH (a Novartis Company) Kundl, Austria.Most of the auxiliaries used for production are bought from approved supply source of Novartis AG, Basel, Switzerland and Sandoz GmbH Austria. Packaging materials are bought from third parties with the global standard set for the pharmaceuticals industries.Apart from producing globally developed research & generics drugs, traditionallyTongi Plant was instrumental in local development of finished pharmaceuticals products e.g. Famoodine, Ciprofloxacin, Omeprazole, Sparfloxacine etc. Since 1997, Tongi Plant is in the export market, after expansion of the plant it became the global supply point for Novartis generics. NBL Tongi Plant is instrumental intransferring technology to many other Novartis manufacturing sires and also acting as a competent center for the products coming out from Tongi Plant. 

You're Reading a Free Preview

Download
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->